Get Critical Health Info

Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Advocacy Issues

| More

Newsflash

11/8/17
FORCE, along with 60 other patient groups, is asking the Senate to preserve medical expense deductions in any forthcoming tax reform legislation.  

10/25/17
We joined over 100 Defense Health Research Consortium orgs in supporting DoD research funding. Learn more...

9/22/17
Check out this new video w/FORCE & 15 other cancer orgs representing patients, physicians, nurses, & social workers. Oppose Graham-Cassidy! See Video...

9/14/17
FORCE reps were in St. Louis today for an ICER hearing on the value and cost of PARP inhibitors for ovarian cancer patients.

Insurance Coverage & Barriers

People affected by hereditary cancer need a variety of health care services including genetic counseling and testing, increased screening, chemoprevention and/or risk-reducing surgeries. In addition, targeted therapies are available for certain hereditary cancers. FORCE identifies possible barriers to care and works to ensure that high-risk individuals have access to the needed interventions via health insurance coverage, financial aid or participation in research.

Insurance Coverage & Barriers

Executive Actions Pose New Challenges for U.S. Health Care

Frustrated by the lack of progress on health care reform, on October 12, President Trump issued an executive order which could undermine the individual and small group health insurance markets. The order allows “junk” association and short-term health plans. The same day, the White House announced that it is planning to halt cost-sharing reduction payments (CSRs) which help health insurance companies offset out-of-pocket medical costs for low-income enrollees, keeping coverage affordable. In essence, without changing or repealing the Affordable Care Act (ACA), these actions authorize federal agencies to modify regulations so that more health plans would be exempt from some of its core requirements. 

Insurance Coverage & Barriers

FORCE Supports Oral Chemotherapy Parity Initiatives

Oral chemotherapy is becoming more common and is the standard of care for many types of cancer. Oral treatment also accounts for about a third of the oncology development pipeline. Importantly, many oral anti-cancer medications do not have IV or injected alternatives, and are the only option for some patients. PARP inhibitors, which hold great promise for treating BRCA-related cancers, are just one example. For this reason, these medications must be as affordable as their IV counterparts. FORCE is supporting the Cancer Drug Coverage Parity Act of 2017, a national legislative initiative which strives to create equal insurance coverage of patient administered and physician administered cancer treatments.

Insurance Coverage & Barriers

Senate Drops ACA Repeal Effort

A bill introduced in the Senate—referred to as the Graham-Cassidy plan—briefly gained momentum but was dropped when it couldn't garner enough support for passage. Facing a deadline of September 30th to pass legislation with a simple majority vote, the controversial bill drew criticism from patient advocacy groups, medical societies, and others. The revised ACA repeal plan would have given states broad waiver authority to eliminate the ACA’s core protections for people with preexisting health conditions. These waivers would have come on top of the proposal’s elimination of the ACA’s marketplace subsidies and Medicaid expansion, radical restructuring of the rest of the Medicaid program, and large cuts to total federal funding for health insurance coverage.

Treatments & Therapies

ICER Review of PARP Inhibitors for Ovarian Cancer

In July 2017, the Institute for Clinical and Economic Review (ICER) released a draft evidence report titled, “Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value.” FORCE has concerns about the report's conclusions as there are significant differences in the patient populations used for comparative data and gaps in the costs used for the value analysis. Additionally, the analysis design does not adequately represent the interests of patients, clinicians, or the hereditary cancer community. FORCE expressed these concerns via written comments and testified at the Midwest CEPAC meeting on September 14, 2017.

Insurance Coverage & Barriers

Statement Sets the Record Straight on AHCA and HR 1313

Recent events related to proposed changes in health care and genetic privacy laws have spurred concern and uncertainty in the hereditary cancer community. Some media stories have disseminated inaccurate information, which has intensified people’s unease. We prepared this briefing to dispel some of the misinformation and allay some of the fears that have been expressed. This statement aims to answer questions and clarify information regarding HR 1313, employer-based wellness programs, and GINA.  It also explains where things stand with repeal and replacement of the ACA, and clarifies what may be considered a pre-existing condition. 

Insurance Coverage & Barriers

Hereditary Cancer Health Care Report

May 4, 2017
Today, the U.S. House of Representatives passed a bill that would repeal much of the Affordable Care Act (ACA) and replace it with a new health care system.The new legislation allows states to seek a waiver from ACA's current requirement that insurers charge people the same for coverage regardless of whether they have a pre-existing condition. It also eliminates mandatory coverage of essential health benefits such as maternity care, mental health, and preventive screenings. It's important to understand that this is only the first in a number of steps required to change the current U.S. health system. 

Screening & Prevention

FORCE Weighs In on Prostate Cancer Screening Guidelines

FORCE recently submitted comments on the USPSTF Draft Recommendation Statement and Evidence Review for Prostate Cancer Screening. Once finalized, these guidelines are utilized by health care providers to determine appropriate screening and care, and to inform insurance coverage decisions on specific preventive services. The Affordable Care Act stipulates that any preventive service receiving a USPSTF rating of “A” or “B” must be covered by most health plans with no copay or cost-sharing for the patient. Consequently, these guidelines impact access to care for members of the hereditary cancer community.

Genetic Testing & Counseling

Comments on Draft Research Plan for BRCA Testing Submitted

FORCE recently submitted comments on the USPSTF Draft Research Plan for BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing. The final Research Plan will be used to guide a review of scientific evidence to develop updated recommendations on BRCA genetic counseling and testing. These guidelines are utilized to inform coverage decisions on specific preventive services. The Affordable Care Act stipulates that any preventive service receiving a USPSTF rating of “A” or “B” must be covered by most health plans with no copay or cost-sharing. As such, these guidelines impact access to care and insurance coverage of services for the cancer community.

Genetic Privacy & Protection

New Legislation Threatens Genetic Privacy

H.R. 1313, the Preserving Employee Wellness Programs Act, garnered a great deal of attention in recent weeks. On March 22nd, we received word that the bill is "on hold" and will not move forward without revisions—including changes to the genetic information requirements. Unfortunately, members of the House Committee on Education and the Workforce indicated that they will push forward with modified legislation. We are working to ensure that any revisions to the proposed legislation reflect the concerns of those affected by hereditary cancer. Updates on this important issue will be provided when they are available. 

Insurance Coverage & Barriers

Election 2016 Update

Members of the FORCE community have reached out with questions and concerns about the implications of the recent election. See our statement on the impact of the 2016 election for people affected by hereditary cancer and our December 2016 blog to learn how the change in administration may affect you and your family. Stay tuned for updates in the coming months.

Have concerns about health insurance? Coverage for pre-existing conditions? Caps on out-of-pocket health care expenditures? We encourage you to call or email your elected officials to tell them what's important to you. Contact info for your current members of Congress can be found at 
www.govtrack.us/congress/members.

Insurance Coverage & Barriers

Insurance Coverage of Annual Screening Mammograms

In early 2016 the U.S. Preventive Services Task Force (USPSTF) released new breast cancer screening guidelines which recommended raising the minimum age for annual screening mammograms for “average risk” women to 50. If implemented, women between the ages of 40 and 49 would likely lose access to yearly breast screening mammography. FORCE was a leader in efforts to curtail the proposed guidelines, preserving 100% insurance coverage of this lifesaving cancer screening for all women starting at age 40.

Genetic Testing & Counseling

Clarification Includes Survivors in BRCA Screening Guidelines

The USPSTF BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing Guidelines are used to determine who is eligible for BRCA genetic counseling and testing with no out-of-pocket costs under the Affordable Care Act. These recommendations were initially interpreted to apply only to women with a family cancer history consistent with the USPSTF criteria, who have not been diagnosed with cancer. In 2015, a clarification was issued indicating that these guidelines also apply to women who have been diagnosed with breast, ovarian, or other cancers. 

Insurance Coverage & Barriers

Medicare Expands Genetic Services Coverage in Some Regions

Four Medicare Area Contractors (MACs) approved Local Coverage Determinations (LCDs) that better align their services with NCCN guidelines in a number of areas such as expanding coverage of genetic testing for individuals who have or had cancer consistent with hereditary cancer syndromes, including men and those affected by prostate and pancreatic cancer; coverage of multigene genetic tests panels if more than one mutation may be indicated; and clarification of the BRCA testing policy for use of the targeted cancer therapy, Lynparza. 

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered